CA3039178A1 - Novel jak1 selective inhibitors and uses thereof - Google Patents

Novel jak1 selective inhibitors and uses thereof Download PDF

Info

Publication number
CA3039178A1
CA3039178A1 CA3039178A CA3039178A CA3039178A1 CA 3039178 A1 CA3039178 A1 CA 3039178A1 CA 3039178 A CA3039178 A CA 3039178A CA 3039178 A CA3039178 A CA 3039178A CA 3039178 A1 CA3039178 A1 CA 3039178A1
Authority
CA
Canada
Prior art keywords
compound
nrr
disease
formula
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3039178A
Other languages
English (en)
French (fr)
Inventor
Congxin Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Highlightll Pharmaceutical Co Ltd
Original Assignee
Tll Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tll Pharmaceutical LLC filed Critical Tll Pharmaceutical LLC
Publication of CA3039178A1 publication Critical patent/CA3039178A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3039178A 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof Pending CA3039178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
US62/403,660 2016-10-03
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3039178A1 true CA3039178A1 (en) 2018-04-12

Family

ID=61831161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039178A Pending CA3039178A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Country Status (20)

Country Link
US (2) USRE49834E1 (OSRAM)
EP (1) EP3509591B1 (OSRAM)
JP (1) JP7089141B2 (OSRAM)
KR (1) KR102399848B1 (OSRAM)
CN (2) CN113214278B (OSRAM)
AU (3) AU2017339417C1 (OSRAM)
CA (1) CA3039178A1 (OSRAM)
DK (1) DK3509591T3 (OSRAM)
EA (1) EA201990523A1 (OSRAM)
ES (1) ES2901216T3 (OSRAM)
HK (1) HK1253040A1 (OSRAM)
HR (1) HRP20211965T1 (OSRAM)
HU (1) HUE058120T2 (OSRAM)
IL (3) IL265358B (OSRAM)
MX (1) MX390005B (OSRAM)
NZ (1) NZ751284A (OSRAM)
PL (1) PL3509591T3 (OSRAM)
PT (1) PT3509591T (OSRAM)
RS (1) RS62695B1 (OSRAM)
WO (1) WO2018067422A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390005B (es) 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
SI3568396T1 (sl) 2017-01-11 2021-04-30 Leo Pharma A/S Novi derivati amino-imidazopiridina koz zaviralci Janus kinaze in njihova farmacevtska uporaba
EA202191170A1 (ru) 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
TW202102222A (zh) * 2019-03-19 2021-01-16 美商英塞特公司 白斑病之生物標記物
CA3142629A1 (en) * 2019-06-06 2020-12-10 Highlightll Pharmaceutical (Hainan) Co., Ltd Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
JP7320628B2 (ja) 2019-06-06 2023-08-03 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド フロイミダゾピリジン化合物の合成方法、フロイミダゾピリジン化合物の結晶形態およびそれらの塩の結晶形態
EP4153566A1 (en) 2020-05-19 2023-03-29 Bayer CropScience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
JP7729845B2 (ja) 2020-06-10 2025-08-26 バイエル、アクチエンゲゼルシャフト 新規殺菌剤としてのアザビシクリル置換複素環
EP4351584A4 (en) * 2021-06-07 2025-04-23 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE
IL313097A (en) * 2021-09-13 2024-07-01 Hangzhou Highlightll Pharmaceutical Co Ltd Methods of treating cns disorders
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
CN101277965A (zh) * 2005-08-04 2008-10-01 西特里斯药业公司 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物
CA2775942A1 (en) * 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
MX2013003913A (es) 2010-10-08 2013-09-26 Abbvie Inc Compuestos de furo [3, 2-d] pirimidina.
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
MX390005B (es) 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.

Also Published As

Publication number Publication date
DK3509591T3 (da) 2021-12-20
CN113214278A (zh) 2021-08-06
IL291265B1 (en) 2023-01-01
RS62695B1 (sr) 2022-01-31
AU2022201061A1 (en) 2022-03-10
IL291267B2 (en) 2023-05-01
EA201990523A1 (ru) 2019-10-31
AU2017339417C1 (en) 2022-06-02
PT3509591T (pt) 2021-12-27
IL291265A (en) 2022-05-01
KR20190057069A (ko) 2019-05-27
IL291265B2 (en) 2023-05-01
PL3509591T3 (pl) 2022-01-31
AU2017339417B2 (en) 2021-11-18
US20190256523A1 (en) 2019-08-22
JP2019537559A (ja) 2019-12-26
IL291267A (en) 2022-05-01
AU2022201058B2 (en) 2023-03-16
ES2901216T3 (es) 2022-03-21
HRP20211965T1 (hr) 2022-03-18
US10738060B2 (en) 2020-08-11
HUE058120T2 (hu) 2022-07-28
NZ751284A (en) 2022-09-30
CN108366994A (zh) 2018-08-03
IL265358B (en) 2022-04-01
EP3509591A1 (en) 2019-07-17
AU2017339417A1 (en) 2019-03-28
USRE49834E1 (en) 2024-02-13
CN108366994B (zh) 2021-10-01
MX390005B (es) 2025-03-20
IL291267B1 (en) 2023-01-01
KR102399848B1 (ko) 2022-05-19
CN113214278B (zh) 2022-10-28
AU2022201058A1 (en) 2022-03-10
HK1253040A1 (zh) 2019-06-06
EP3509591A4 (en) 2020-03-25
MX2019003649A (es) 2019-08-14
WO2018067422A1 (en) 2018-04-12
BR112019005969A2 (pt) 2019-06-18
JP7089141B2 (ja) 2022-06-22
AU2022201061B2 (en) 2023-03-16
EP3509591B1 (en) 2021-11-17
IL265358A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
AU2022201061B2 (en) Novel Jak1 selective inhibitors and uses thereof
JP6389511B2 (ja) 癌を治療するための、ｎｉｋ阻害剤としての３−（２−アミノピリミジン−４−イル）−５−（３−ヒドロキシプロピニル）−１ｈ−ピロロ［２，３−ｃ］ピリジン誘導体
TWI406864B (zh) 化合物
EP3473626B1 (en) Pyrrolopyrimidine crystal for preparing jak inhibitor
CN120535513A (zh) Rip1抑制性化合物以及制备和使用其的方法
JP2010524911A (ja) ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
CN107531682A (zh) B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
HUE034807T2 (en) New quinoline-substituted compound
KR20170095239A (ko) ＰＩ３Ｋβ 저해제로서의 이미다조피리다진 유도체
CN106232602A (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
HK40004735B (en) Novel jak1 selective inhibitors and uses thereof
BR112019005969B1 (pt) Inibidores seletivos de jak1 e usos dos mesmos
HK40047523B (en) Novel jak1 selective inhibitors and uses thereof
HK40047523A (en) Novel jak1 selective inhibitors and uses thereof
EA040948B1 (ru) Селективные ингибиторы jak1 и их применение
HK40082783A (en) Rip1 inhibitory compounds and methods for making and using the same
HK1142067A (en) 9-(pyraxzol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220718

EEER Examination request

Effective date: 20220718

EEER Examination request

Effective date: 20220718

EEER Examination request

Effective date: 20220718

EEER Examination request

Effective date: 20220718

EEER Examination request

Effective date: 20220718

EEER Examination request

Effective date: 20220718